On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.
Stocks To Buy Now


Unveiling the Neuroprotective Power of CNMAu8 A Promising Breakthrough in Neurodegenerative Disease Treatment

by Elaine Mendonça

On September 28, 2023, Clene Inc. (NASDAQ: CLNN) made an exciting announcement regarding their groundbreaking research on the investigational drug CNM-Au8. In a scientific paper published in the esteemed journal Small, Clene Inc. revealed the catalytic mechanism of action behind the therapeutic properties of CNM-Au8.

The study showcased the remarkable neuroprotective abilities of CNM-Au8, attributing its success to its unique catalytic activity. When exposed to toxins that typically lead to neuronal death, CNM-Au8 treatment exhibited a remarkable ability to promote cell survival and preserve the intricate network of neurites.

To truly understand the underlying mechanisms responsible for CNM-Au8’s neuroprotective function, extensive studies were conducted. These studies focused on characterizing the catalytic reactions facilitated by CNM-Au8, aiming to unravel how it effectively regulates cellular health and metabolism. The findings were nothing short of groundbreaking, shedding light on the exceptional therapeutic potential of CNM-Au8.

The distinct mechanism of action exhibited by CNM-Au8, coupled with its wide applicability in preserving neuronal health, positions it as a promising new treatment for various neurodegenerative diseases. This research opens up exciting possibilities for addressing multiple assaults on neuronal health and offers hope for patients worldwide.

Clene Inc. (NASDAQ: CLNN) Stock Performance and Financial Indicators: September 28, 2023 Analysis

CLNN stock had a relatively stable performance on September 28, 2023, with a previous close of $0.53 and an open of $0.52. Throughout the day, the stock fluctuated within a range of $0.52 to $0.55. The trading volume was 533,547 shares, which is slightly higher than the average volume of 528,357 shares over the past three months. The market capitalization of CLNN stands at $59.5 million.

Looking at the financial indicators, CLNN has experienced significant challenges in terms of earnings growth. The earnings growth for the previous year was -190.01%, indicating a substantial decline. However, there is no available information on earnings growth for the current year or the next five years. The revenue growth for the last year was also negative, with a decline of 34.58%.

The price-to-earnings (P/E) ratio for CLNN is not provided (NM), suggesting that the company may have negative earnings or no earnings at all. The price/sales ratio is 137.85, indicating that investors are willing to pay a premium for each dollar of sales generated by the company. The price/book ratio is 10.71, which suggests that the stock may be overvalued based on its book value.

Clene Inc. (NASDAQ: CLNN) operates in the health technology sector, specifically in the pharmaceuticals: major industry.

The next reporting date for CLNN is November 7, 2023. Analysts forecast an earnings per share (EPS) of -$0.10 for this quarter. The annual revenue for the previous year was $473,000, while the annual profit was -$29.9 million. The net profit margin for CLNN is a staggering -6,325.16%, indicating significant losses.

Investors should carefully consider these factors before making any investment decisions regarding CLNN stock.

CLNN Stock Shows Impressive Performance with Potential for Significant Growth: Analysts Median Target Estimate

CLNN stock had an impressive performance on September 28, 2023, based on the information provided by CNN Money. The 12-month price forecasts from six analysts for Clene Inc. had a median target of $5.00, with a high estimate of $10.00 and a low estimate of $4.00. This median estimate represents a remarkable increase of 825.93% from the last recorded price of $0.54.

The consensus among the six polled investment analysts is to buy stock in Clene Inc., and this rating has remained steady since September. This indicates a positive sentiment towards the company’s future prospects.

It is important to note that the stock’s current performance is not solely based on the information provided for September 28, 2023. The data source does not provide specific details about the stock’s performance on that particular day. However, the 12-month price forecasts and the consensus among analysts suggest a positive outlook for Clene Inc.

In terms of financials, the current quarter’s earnings per share for Clene Inc. were reported at -$0.10. Additionally, the company’s sales for the same quarter amounted to $117.8K. These figures indicate that Clene Inc. may be experiencing some financial challenges in the short term.

Investors should keep an eye on Clene Inc.’s upcoming reporting date, which is set for November 7. This report may provide more insights into the company’s financial performance and future prospects.

Overall, the information provided suggests that Clene Inc.’s stock has the potential for significant growth, as indicated by the high median target estimate from analysts. However, investors should carefully consider the company’s financial performance and any upcoming reports before making investment decisions.

For more information on Clene visit Clene Inc. (NASDAQ: CLNN)

Third-Party Content

The STBN website may contain Third-Party Content articles and other content submitted by third parties, including articles submitted through the STBN Premium Partnership Program. All opinions, statements and representations expressed by such third parties are theirs alone and do not express or represent the views and opinions of STBN or its affiliates and owners. Content created by third parties is the sole responsibility of such third parties, and STBN does not endorse, guarantee or make representations concerning the accuracy and completeness of any third-party content. You acknowledge that by STBN providing you with this internet portal that makes accessible to you the ability to view third party content through the STBN site, STBN does not undertake any obligation to you as a reader of such content or assume any liability relating to such third-party content. STBN expressly disclaims liability relating to such third-party content. STBN and its members, affiliates, successors, assigns, officers, directors, and partners assume no responsibility or liability that may arise from the third-party content, including, but not limited to, responsibility or liability for claims for defamation, libel, slander, infringement, invasion of privacy and publicity rights, fraud, or misrepresentation, or an private right of action under the federal securities laws of the United States or common law. Notwithstanding the foregoing, STBN reserves the right to remove third-party content at any time in its sole discretion. By viewing this third-party content, you acknowledge that you have viewed, read fully, accepted and agreed to all terms of the Disclaimer at https://www.stockstobuynow.com/disclaimer/.

The disclaimers on the STBN website are applicable to all content provided by STBN, wherever published or re-published are at: https://www.stockstobuynow.com/disclaimer/

From Our Blog

GEMXX Corp. (GEMZ) Releases Positive Q2 2023 Results, Provides 2023 Business and Mining Updates

December 7, 2023

GEMXX (OTC: GEMZ), a company specializing in gold mining and production and distribution of jewelry and gemstones on a global scale, supplying its own mined resources, shared positive financial results for the second quarter of fiscal 2023, ended September 20, 2023, and provided business and mining updates. Key highlights included a near-60% year-over-year increase in […]

Rotate your device 90° to view site.